A newly launched U.S. government platform designed to lower prescription drug costs is facing renewed scrutiny after data showed that several medicines listed on it remain more expensive than comparable prices in the United Kingdom.

The platform, known as TrumpRx, was introduced as part of President Donald Trump’s broader effort to deliver lower drug prices to American consumers by aligning costs with those paid in other developed nations.

Built on a “most favored nation” framework, the initiative aims to ensure Americans benefit from the lowest available international pricing for branded medicines.

However, recent comparisons indicate that this goal has not yet been fully realized across all products.

Analysis of the initial list of medicines available on the platform found that roughly one-third are priced higher than in the UK, including widely used treatments for conditions such as arthritis, diabetes and respiratory illnesses.

In some cases, UK prices were reported to be significantly lower, reflecting differences in national pricing systems and procurement models.

The findings come as the administration continues to expand the program, which currently features a limited selection of medicines offered through direct purchasing arrangements with participating pharmaceutical companies.

These agreements are designed to bypass traditional insurance channels and provide more transparent, upfront pricing for consumers.

Officials have emphasized that the initiative represents an important step toward correcting long-standing imbalances in global drug pricing, where American patients have historically paid more than their counterparts in other advanced economies.

The administration has also highlighted ongoing negotiations with drugmakers and international partners aimed at narrowing these disparities over time.

The United Kingdom operates a tightly regulated pricing system for medicines, enabling its public health service to secure lower costs through centralized negotiations and value-based assessments.

By contrast, the U.S. system has traditionally relied on a more fragmented structure involving private insurers and market-driven pricing.

Despite the current discrepancies, the TrumpRx program is expected to evolve as more pharmaceutical companies join and additional medicines are added.

The administration has signaled that continued engagement with industry stakeholders will be central to achieving its objective of delivering globally competitive prices for American patients.

The development underscores both the ambition and the complexity of reshaping pharmaceutical pricing in the United States, as policymakers seek to balance affordability, innovation and international market dynamics.